EMA Authorised: Degarelix Accord (degarelix acetate) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA has authorised Degarelix Accord (degarelix acetate) for prostatic neoplasms, marking an approved drug in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Degarelix Accord (degarelix acetate)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Accord Healthcare S.L.U.. Decision date: 29/09/2023